AvenCell Europe GmbH
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (NCT05949125) | AvenCell Europe GmbH | 2024-01-03 |
| Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (NCT04633148) | AvenCell Europe GmbH | 2020-11-23 |
| Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (NCT04230265) | AvenCell Europe GmbH | 2020-01-28 |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (NCT03927573) | AvenCell Europe GmbH | 2019-04-15 |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (NCT03516760) | AvenCell Europe GmbH | 2018-04-11 |
Track AvenCell Europe GmbH automatically
Every clearance here is in the API, with alerts when new ones post.